A case series of serious and unexpected adverse drug reactions under treatment with cariprazine

Reporting of new or unexpected adverse drug reactions of medicines that are subject to additional monitoring (“black triangle” label), such as the antipsychotic drug cariprazine, is of paramount importance to improve pharmacotherapy safety.

[1]  D. Copolov,et al.  Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia , 2020, CNS Drugs.

[2]  S. Stahl,et al.  Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data , 2020, Therapeutic advances in psychopharmacology.

[3]  K. Demyttenaere,et al.  Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis , 2019, CNS Drugs.

[4]  J. Malinovsky.  An Introduction to Pharmacovigilance, 2nd ed , 2018, Anesthesia & Analgesia.

[5]  M. Kołaczkowski,et al.  The preclinical discovery and development of cariprazine for the treatment of schizophrenia , 2018, Expert opinion on drug discovery.

[6]  A. Altamura,et al.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update , 2018, Clinical Pharmacokinetics.

[7]  N. Kanahara,et al.  Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice , 2017, Journal of psychopharmacology.

[8]  Michael Diduch,et al.  Review of cariprazine in management of psychiatric illness. , 2017, The mental health clinician.

[9]  H. Nasrallah,et al.  The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis , 2017, BMC Psychiatry.

[10]  P. Czobor,et al.  Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial , 2017, The Lancet.

[11]  Ashley Tewksbury,et al.  Management of antipsychotic-induced hyperprolactinemia , 2016, The mental health clinician.

[12]  L. Citrome.  Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability , 2013, Expert opinion on drug metabolism & toxicology.

[13]  J. López-Sendón,et al.  Drug-Induced Parkinsonism in the Elderly , 2012, Drugs & Aging.

[14]  O. Rascol,et al.  Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France , 2011, Movement disorders : official journal of the Movement Disorder Society.

[15]  Eva Schmidt,et al.  Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile , 2010, Journal of Pharmacology and Experimental Therapeutics.

[16]  P. Waller,et al.  An Introduction to Pharmacovigilance , 2009 .

[17]  J. Adán-Manes,et al.  Aripiprazole in combination with other antipsychotic drugs may worsen psychosis , 2009, Journal of clinical pharmacy and therapeutics.

[18]  M. C. Catalano,et al.  Acute akathisia associated with quetiapine use. , 2005, Psychosomatics.

[19]  J. Williamson,et al.  DRUG-INDUCED PARKINSONISM IN THE ELDERLY , 1984, The Lancet.

[20]  Psychiatrischen Pharmakotherapie.  Kompendium der Psychiatrischen Pharmakotherapie , 2019 .

[21]  Ich Harmonised,et al.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .

[22]  S. Ramaswamy,et al.  Aripiprazole possibly worsens psychosis. , 2004, International clinical psychopharmacology.